RBC Capital lowered the firm’s price target on Pacira to $37 from $42 but keeps an Outperform rating on the shares after its Q2 earnings beat and affirmed guidance. The company continues to execute on delivering positive Exparel numbers through the first half of the year, though focus remains squarely on ongoing patent litigation vs. eVenus, with court decision likely to come August 1st, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PCRX:
- Pacira (PCRX) Q2 Earnings Cheat Sheet
- Pacira negative patent ruling most likely outcome, says JPMorgan
- CMS proposes new reimbursement for Exparel in outpatient surgical enviroments
- Centers for Medicare and Medicaid Propose New Reimbursement for EXPAREL in All Outpatient Surgical Environments Beginning January 1, 2025
- Intuit initiated, Charter downgraded: Wall Street’s top analyst calls